GlassScriptPhysician profile
Matthew B Bowles
NPI 1942236948
$8,864.61
in general payments reported to CMS, 2019-2025
33 companies · $1,726 in 2025
The $1,726 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,364 · 2022: $2,508 · 2023: $1,776 · 2024: $1,490 · 2025: $1,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,992.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,285.24 | 2021-2025 | |
| Medtronic, INC. | $1,239.90 | 2021-2025 | Endurant Iis, Linq II, Reveal Linq |
| Boston Scientific Corporation | $965.77 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Ingevity+ |
| E.R. Squibb & Sons, L.L.C. | $827.25 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $720.50 | 2021-2025 | Brilinta, Wainua, Farxiga |
| Amgen INC. | $450.86 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $368.48 | 2021-2023 | Xarelto |
| Irhythm Technologies, INC. | $348.08 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $228.28 | 2022-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $222.64 | 2021-2025 | Lifevest |
| Pfizer INC. | $219.07 | 2021-2025 | |
| Abbott Laboratories | $218.19 | 2021-2023 | Jot Dx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.12 | 2021-2023 | Ofev, Jardiance |
| Baxter Healthcare | $190.61 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor, Preveleak |
| Astellas Pharma US INC | $182.69 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $171.69 | 2024 | (Ck4) Mcot, (Cm9) Amb Mon & Diag Und |
| Bayer Healthcare Pharmaceuticals INC. | $134.43 | 2021-2025 | |
| Gilead Sciences, INC. | $127.37 | 2021-2023 | Veklury |
| Novo Nordisk INC | $125.41 | 2023-2025 | Ozempic, Wegovy |
| Bridgebio Pharma, INC. | $120.14 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $117.70 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $63.53 | 2022-2023 | Arcalyst |
| Scpharmaceuticals INC. | $46.57 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $43.64 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $43.54 | 2023 | Inpefa |
| Teleflex LLC | $40.00 | 2022-2023 | Manta |
| Lifenet Health | $28.00 | 2025 | Theragenesis Wound Matrix |
| United Therapeutics Corporation | $25.87 | 2023 | Tyvaso |
| Inogen, INC. | $22.59 | 2022 | |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Abiomed | $19.93 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.81 | 2023 | Jynarque |
| Medicomp INC | $16.71 | 2023 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bowles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.